Health
TRACE International Releases the 2024 Bribery Risk Matrix
ANNAPOLIS, Md., Nov. 19, 2024 /PRNewswire/ -- TRACE, a non-profit international business association dedicated to anti-bribery, compliance, and good governance, has released the 2024 Bribery Risk Matrix, measuring business bribery risk in 194 jurisdictions. Originally published in 2014 to meet a...
2024-11-19 21:00
844
Hankyung.com introduces: Unmissable BFCM Deal on Amazon: Get EXTREME DUAL ARGININE PLUS, Free Shipping, and Subscribe & Save Options!
https://img.hankyung.com/pdsdata/pr.hankyung.com/uploads/2024/11/image01-1.jpg
2024-11-19 21:00
1014
Health2Sync Partners with Singapore Health Promotion Board and Abbott to Launch Innovative DigiCoach Program Tackling Pre-diabetes and Obesity
* "DigiCoach program" is a pilot program by Singapore Health Promotion Board, Health2Sync, and Abbott that aims to help individuals with pre-diabetes or high BMI prevent or delay the onset of diabetes. * Participants can use a continuous glucose monitoring (CGM) device and the Health2Sync mob...
2024-11-19 21:00
1031
Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study
Highlights: * Positive preclinical results in human in vitro iPSC Motor Neuron models of Amyotrophic Lateral Sclerosis (ALS) * Neurizon's lead drug NUZ-001 and its major active metabolite significantly and dose-dependently prevented the aggregation of TAR DNA-binding protein 43 (TDP-43) by ~...
2024-11-19 20:30
808
Xinhua Silk Road: Inheriting traditions while promoting innovation, Chinese pharmaceutical company contributes to TCM globalization
BEIJING, Nov. 19, 2024 /PRNewswire/ -- With continuous advancement of the Belt and Road Initiative, Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. has been actively promoting the globalization of traditional Chinese medicine (TCM) through both inheriting traditional assets and engaging in mode...
2024-11-19 20:29
2690
Brii Bio Delivers First Head-to-Head Comparison of siRNA (Elebsiran) and PEG-IFNα Combination versus PEG-IFNα Alone at AASLD's The Liver Meeting® 2024, Demonstrating Higher Loss of HBV Surface Antigen by Combining with siRNA
48-week end-of-treatment data from the ongoing Phase 2 ENSURE study clearly demonstrated the added benefits of elebsiran towards achieving a higher functional cure rate in combination with PEG-IFNα Data from multiple combination studies sponsored by the Company and its partner continue to suppor...
2024-11-19 19:30
1516
Digital Medicine Society Launches Resources to Navigate Global Digital Health Regulatory Pathways
Resources will speed the expansion of digital health products worldwide, improving global patient access BOSTON, Nov. 19, 2024 /PRNewswire/ -- Today, the Digital Medicine Society (DiMe) unveiled a suite of resources to guide industry in evaluating international regulatory pathways. These resourc...
2024-11-19 19:00
936
SiPH Collaborates with IBM to Enhance Pathology Information System with Computational Advances and AI to Support Patients in Thailand and ASEAN
BANGKOK, Nov. 19, 2024 /PRNewswire/ -- Siriraj Piyamaharajkarun Hospital (SiPH), operating under Faculty of Medicine Siriraj Hospital, today announced a successful transformation of its Pathology Information System (PIS) using advanced computational technologies and artificial intelligence. In c...
2024-11-19 17:07
1345
RiDYMO® Platform Drives New Breakthroughs in highly potent PLK1 Inhibitors Development
BEIJING, Nov. 19, 2024 /PRNewswire/ -- With the support of the RiDYMO® platform, we are able to comprehensively explore various potential targets in drug development, including protein-protein interactions, kinases, GPCRs, ion channels, and transcription factors. Polo-like kinase 1 (PLK1) is a h...
2024-11-19 16:00
874
TAHO Pharmaceuticals Initiates U.S. Phase III Clinical Trial of TAH3311 Antithrombotic Oral Dissolving Film, Dosing First Subjects
TAIPEI, Nov. 19, 2024 /PRNewswire/ -- TAHO Pharmaceuticals Ltd. announced the dosing of the first subjects in its U.S. Phase III clinical trial for its lead product, TAH3311, an innovative antithrombotic oral dissolving film (ODF). In July 2023, the U.S. Food & Drug Administration (FDA) accepted T...
2024-11-19 14:08
967
Beyond Living Unveils Malaysia's First Non Wearable AI-Driven SOS Device
KUALA LUMPUR, Malaysia, Nov. 19, 2024 /PRNewswire/ -- Proudly Malaysian-born, Beyond Living introduces the AI SOS Device,Malaysia's first non-wearable, AI-powered life-saving solution. The device is tailored to meet theneeds of active lifestyle athletes, elderly, adults living alone and individua...
2024-11-19 10:18
1308
GHIT Fund Awarded Open Philanthropy Grant to Expand Funding Sources for Global Health R&D
TOKYO, Nov. 19, 2024 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund is pleased to announce that Open Philanthropy, a grantmaking organization based inSan Francisco, California, has awarded funding for efforts to cultivate new partnerships and secure resources from the private...
2024-11-19 09:00
1091
SK Biopharmaceuticals Seals 1st Actinium-225-Based Collaborative Research Agreement with Korea Institute of Radiological and Medical Sciences as Steps Toward Becoming Global Radiopharmaceutical Therapy Player
* SK Biopharmaceuticals, Korea Institute of Radiological and Medical Sciences collaborate on discovering and developing radiopharmaceutical drug candidates using analpha-particle emitting radioisotope, actinium-225, for potential cancer treatments * The two sides aim to submit an Investigatio...
2024-11-19 08:00
1504
Everest Medicines Announces NEFECON® Has Received Full Approval from South Korea's Ministry of Food and Drug Safety (MFDS) for the Treatment of Primary IgA Nephropathy
SHANGHAI, Nov. 19, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that NEFECON® has received full appro...
2024-11-19 07:40
1397
Telix to Add FAP-Targeting Candidates to Theranostic Pipeline
MELBOURNE, Australia, Nov. 19, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces it will expand its theranostic pipeline with new assets targeting Fibroblast Activation Protein (FAP), one of the most promising pan-cancer targets in nucl...
2024-11-19 06:24
1408
Celltrion presents additional data from phase III randomized controlled trials to further support biosimilarity for CT-41 (biosimilar candidate of denosumab) and CT-P47 (biosimilar candidate of tocilizumab) at American College of Rheumatology (ACR) Convergence 2024
* 78-Week results from Phase III randomized controlled trial (RCT) including switching data from reference denosumab to CT-P41 (biosimilar candidate of denosumab) demonstrate comparable efficacy and safety results; Results support the therapeutic equivalence of CT-P41 and reference denosumab in...
2024-11-19 02:15
1256
WAT Medical Continues Support for Red Cross and Veterans Association
VANCOUVER, BC, Nov. 18, 2024 /PRNewswire/ -- WAT Medical Enterprise Ltd. proudly reaffirms its commitment to community support by donating to the American Red Cross and the American Veterans Association. These donations are part of the company's pledge to contribute a portion of the proceeds from...
2024-11-18 22:30
837
Nasdaq-Listed Prenetics and David Beckham Officially Launch IM8 Health
Beckham is a strategic investor in Prenetics and Co-Founding Partner for IM8 IM8 launch marks a bold entry into the $187 billion global consumer health market Launch follows recently announced Prenetics' acquisition of Europa, one of the largest sports nutrition distributors in the U.S. IM8 is ...
2024-11-18 22:23
1141
Lunit Announces Collaboration with AstraZeneca to Develop AI-Powered Digital Pathology Risk Assessment Tools for NSCLC
Collaboration to harness Lunit SCOPE Genotype Predictor for rapid and convenient prediction of non-small cell lung cancer driver mutations SEOUL, South Korea, Nov. 18, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, ...
2024-11-18 22:00
1267
C Ray Therapeutics Completes Over $100 Million Series A+ Financing, Jointly Led by SCGC and TaiLong Capital
CHENGDU, China, Nov. 18, 2024 /PRNewswire/ -- In November 2024, C Ray Therapeutics (Chengdu) Co., Ltd. (hereinafter referred to as "C Ray"), an innovative enterprise in the field of radiopharmaceuticals, announced the completion of its Series A+ financing round exceeding$100 million. This round ...
2024-11-18 22:00
1350
Week's Top Stories
Most Reposted
Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 305 media titles]
2024-11-20 13:29Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 301 media titles]
2024-11-21 10:30Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 299 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
[Picked up by 296 media titles]
2024-11-15 15:25
Most Read
Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
2024-11-15 15:25
8676
How "small apples" march into "big industry" in Yan'an
2024-11-15 17:39
5434
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
4839